Sears (SHLD), Noodles (NDLS), Celldex Therapeutics (CLDX), Hanesbrands (HBI), CPI Card (PMTS), GNC, & Alexion (ALXN) are laggards with turnaround potential.
Celldex stock loss is the result of Rintega, but Glenbatumaumab, or CDX-011 is what pushed CLDX stock higher before. It could happen again.
These biotech stocks are all prime M&A targets: Gilead Sciences Inc, Alexion Pharmaceuticals, Inc., ACADIA Pharmaceuticals Inc., Sarepta Therapeutics Inc, Intercept Pharmaceuticals Inc, Juno Therapeutics Inc, Kite Pharma Inc, Regeneron Pharmaceuticals Inc, Biogen Idec, and Celldex Therapeutics, Inc.
RAD stock performance does not reflect the near-term Rite Aid buyout, and while the Walgreens-Rite Aid merger looks like a sure thing, investors need to remember CLDX stock when considering “sure things” in the market.